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Abstract
The heart failure epidemic continues to rise with coronary artery disease as one of its main causes. Novel concepts for risk 
stratification to guide the referring cardiologist towards revascularization procedures are of significant value. Myocardial 
perfusion imaging using single-photon emission computed tomography (SPECT) agents has demonstrated high accuracy 
for the detection of clinically relevant stenoses. With positron emission tomography (PET) becoming more widely available, 
mainly due to its diagnostic performance in oncology, perfusion imaging with that modality is more practical than in the 
past and overcomes existing limitations of SPECT MPI. Advantages of PET include more reliable quantification of absolute 
myocardial blood flow, the routine use of computed tomography for attenuation correction, a higher spatiotemporal resolu-
tion and a higher count sensitivity. Current PET radiotracers such as rubidium-82 (half-life, 76 s), oxygen-15 water (2 min) 
or nitrogen-13 ammonia (10 min) are labeled with radionuclides with very short half-lives, necessitating that stress imaging 
is performed under pharmacological vasodilator stress instead of exercise testing. However, with the introduction of novel 
18F-labeled MPI PET radiotracers (half-life, 110 min), the intrinsic advantages of PET can be combined with exercise test-
ing. Additional advantages of those radiotracers include, but are not limited to: potentially improved cost-effectiveness due 
to the use of pre-existing delivery systems and superior imaging qualities, mainly due to the shortest positron range among 
available PET MPI probes. In the present review, widely used PET MPI radiotracers will be reviewed and potential novel 
18F-labeled perfusion radiotracers will be discussed.
Keywords Coronary artery disease · Precision medicine · Positron emission tomography · Myocardial perfusion imaging · 
18F-flurpiridaz · 18F-FBnTP
Introduction
The heart failure (HF) epidemic continues to rise with an 
estimated future financial burden of $70 billion in the year 
2030 [1, 2]. Notably, HF has been recently further subclas-
sified into HF with reduced ejection fraction (HFrEF), with 
preserved ejection fraction (HFpEF), and an intermediate 
group (HF with mid-range ejection fraction, HFmrEF) [3, 4]. 
However, one of the main characteristics of either HFrEF, 
HFpEF or HFmrEF is coronary artery disease (CAD, in up 
to 54% of the cases) [3, 5, 6] and therefore, its reliable detec-
tion, preferably at an early stage of disease, is as relevant as 
ever [7]. As a result of these considerations, novel strategies 
for the assessment of flow-limiting coronary artery stenoses 
have been extensively investigated and myocardial perfusion 
imaging (MPI) has been an important part of evaluating for 
this pathology. The most commonly used radiotracers for 
MPI are the single-photon emission computed tomography 
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(SPECT) agents 99mTc-labeled sestamibi and tetrofosmin, 
as well as thallium-201 (201TI) [8]. In general, the use of 
positron emission tomography (PET) is expanding world-
wide, mainly due to its superior diagnostic performance in 
oncology [9, 10]. Thus, MPI may benefit from the increasing 
installed base of latter imaging modality, as PET may pro-
vide advantages over SPECT MPI imaging. First, PET has 
a higher spatiotemporal resolution in comparison to SPECT 
and a higher count sensitivity. In this light, several studies 
have already reported on the superior imaging characteristics 
and higher accuracy of PET MPI compared to conventional 
SPECT MPI [11, 12]. Moreover, PET includes attenuation 
correction on a routine basis, as hybrid systems equipped 
with computed tomography (CT) are routinely installed, 
which also allows for anatomic co-registration [13]. Apart 
from that, with traditional PET agents, both rest and stress 
images can be acquired during one single study, mainly due 
to the shorter half-life of PET agents [14] and PET has also 
opened the door for reliable quantification of absolute myo-
cardial blood flow (MBF) [15, 16].
Nonetheless, expensive production procedures with on-
site cyclotrons are needed for short-half-life agents [14]. 
This is in contradistinction to recent developments of novel 
18F-labeled radiotracers, which may overcome some of the 
hurdles to adoption of established PET MPI agents. First, 
18F-labeled imaging probes for MPI may be distributed using 
delivery systems from central cyclotron facilities. Second, 
the longer half-life of 18F-labeled MPI agents also allows 
for delayed imaging protocols. From a practical standpoint, 
exercise stress testing outside of the scanner is feasible [17]. 
This manuscript reviews this novel class of PET radiotrac-
ers for MPI. Among those, 18F-flurpiridaz (also previously 
referred as 18F-BMS747158-02) and 18F-fluorobenzyltriphe-
nyl-phosphonium (18F-FBnTP) have been extensively evalu-
ated and thus, will be further discussed.
Clinical PET radiotracers for MPI 
and advantages of 18F‑labeled radiotracers
To date, the clinically used PET MPI agents are rubidium 82 
(82Rb, half-life, 76 s), oxygen-15-water (15O-water, half-life 
2 min) and nitrogen-13-ammonia (13N-ammonia, half-life, 
10 min) [18]. For the production of 82Rb, a commercially 
available strontium 82 generator is needed, and the high 
cost for a monthly replacement ($20,000) is a consideration 
for practitioners as to what extent 82Rb PET MPI can be 
employed in clinical routine [17]. Further drawbacks include 
its ultrashort half-life and the lowest first-pass extraction 
(65%) among all available PET MPI agents. In addition, the 
maximum kinetic energy of positrons emitted during 82Rb 
decay is much higher than that of 13N and 18F [19]. The latter 
aspect may have an impact on image quality: high-energy 
positrons have a long average distance to annihilation and, 
therefore, the spatial resolution is lower relative to other 
radionuclides with lower positron energies [17]. The pro-
duction of 15O-water PET depends on a cyclotron unit and 
it is seen as the gold standard for flow quantification, as 
it freely diffuses across the cardiomyocyte membrane and 
produces ideal flow measurements [20]. However, its noisy 
low-count imaging quality as well as necessity of complex 
kinetic modeling limits its clinical use [18]. 13N-ammonia is 
approved by the United States Food and Drug Administra-
tion and has a very good image quality, but it also requires 
a costly on-site cyclotron [18, 21].
Notably, use of 18F radionuclides may overcome these 
limitations of commonly used PET MPI radiotracers. Advan-
tages of 18F as a radionuclide include, but are not limited to:
(I) 18F has a relatively long physical half-life of 110 min, 
which allows for the use of delivery systems [22] and 
such an approach has already been proven to be cost-
effective for 2-deoxy-2-18F-fluoro-d-glucose (18F-FDG) 
[23];
(II) 18F has the shortest positron range in tissue compared 
to other established MPI PET radionuclides [19], and, 
thus, it may have the highest spatial resolution [17];
(III) the lower positron energy with higher positron yield 
allows for injection of a considerably lower amount of 
radioactivity [13];
(IV) its long half-life opens the door for delayed imaging 
protocols (e.g. for assessment of blood flow alterations 
at late scan time-points) [24];
(V) due to the short half-life of currently used PET MPI 
agents, stress imaging is only feasible while placing 
the patient under pharmacological stress. Notably, 
18F-labeled radiotracers may overcome this limitation 
by allowing for physical exercise stress testing outside 
of the PET device [17, 25, 26].
To date, the most extensively studied 18F-labeled radi-
otracer for PET MPI is 18F-flurpiridaz (Fig. 1).
18F‑labeled radiotracers for MPI: 
18F‑flurpiridaz
Preclinical evaluation
18F-flurpiridaz has demonstrated favorable imaging char-
acteristics for MPI in preclinical studies: As a derivative 
of the pyridazinone insecticide pyridaben, it has a high 
binding affinity towards mitochondrial complex I, with a 
considerable high first-pass extraction of > 90% as meas-
ured in an isolated perfused heart setup [27, 28]. Com-
paring 18F-flurpiridaz with the established SPECT agent 
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99mTc sestamibi in a biodistribution rat study, the cardiac 
uptake of the 18F-labeled agent was significantly higher at 
both early (15 min) and late time points (120 min). This 
experiment was followed by an isolated rabbit heart perfu-
sion study and net 18F-flurpiridaz cardiac uptake increased 
to a greater extent than that of 201TI or 99mTc sestamibi at 
physiologically relevant flow rates. Moreover, an in vivo 
PET study demonstrated almost no lung uptake and rapid 
liver clearance in rats, rabbits, and primates (pronounced 
washout between 5 and 15 min). In addition, a rat model 
of coronary occlusion also showed an excellent correlation 
with 18F-flurpiridaz uptake and histopathological findings 
[29]. These findings were further corroborated in a chronic 
myocardial infarction (MI) model in rabbits (left coronary 
artery occlusion, followed by recovery phase over 1 month): 
compared to controls, a clear defect could be appreciated in 
the left ventricular wall. The promising safety profile of this 
imaging agent was further confirmed by electrocardiogram 
assessments in both controls and MI rabbits [30]. Huisman 
et al. also used the Langendorff method and investigated 
the first-pass extraction of 18F-flurpiridaz in isolated per-
fused rat hearts, on which the radiotracer demonstrated a 
high and flow-independent myocardial first-pass extraction 
fraction. Thus, 18F-flurpiridaz may hold the promise of a 
linear correlation between radiotracer uptake and cardiac 
blood flow [28]. Higuchi and coworkers tested 18F-flurpiri-
daz in rats in vivo. Normal healthy control rats were found 
to have a homogoneous delineation of the myocardium up 
to 2 h after tracer injection. However, for the permanent 
occlusion model, the defect size remained stable over the 
entire imaging protocol (15–115 min). This was in con-
tradistinction to the transient ischemia model: reperfusion 
after short, transient ischemia of 3 min showed radiotracer 
redistribution to the induced defect (i.e. tracer redistribution 
after reperfusion). Radiotracer reinjection further enhanced 
the normalization process. The concept of redistribution 
is based on underperfused but viable myocardium, which 
retains the radiotracer while it washes out of normal myo-
cardial areas, i.e. initial defects appear to normalize [31]. 
The clinical application are diagnosis of CAD and most 
importantly, for the assessment of tissue viability, e.g. by 
radiotracer injection under physical stress with early and 
delayed imaging protocols, which allows to monitor such 
redistribution closely over time. Figure 2 shows the superior 
imaging characteristics of 18F-flurpiridaz PET compared to 
a common PET MPI agent, 13N-ammonia, in (A) healthy 
rats and (B) in a rat model after coronary artery occlu-
sion. The 18F-labeled radiotracer demonstrated improved 
contrast and higher resolution, resulting in better delinea-
tion of induced lesions, despite a higher injected dose of 
13N-ammonia relative to 18F-flurpiridaz. For the 18F-labeled 
Fig. 1  Overview of the 
herein reviewed 18F-labeled 
PET radiotracers for MPI, 
namely 18F-flurpiridaz and 
18F-fluorobenzyltriphenyl-phos-
phonium (18F-FBnTP)
Fig. 2  a Short-axis 18F-flurpiridaz PET in a healthy rat at 15, 45 and 
115  min post-injection. The left ventricular myocardium showed 
excellent contrast to surrounding tissues. 13N-ammonia PET at 
10  min in a coronal view. Regions of interest placements are dis-
played in white box. b Short-axis images of rat hearts 1 week after 
coronary artery occlusion using 18F-flurpiridaz and 13N-ammonia 
PET. The induced 18F-flurpiridaz uptake defect visualized at 15 min 
corresponded precisely to the defect in 13N-ammonia images. How-
ever, 18F-flurpiridaz demonstrated improved contrast and higher 
resolution resulting in better delineation of induced lesions, despite 
a higher injected dose of 13N-ammonia (57 MBq) versus 18F-flurpiri-
daz (37  MBq). The inferior/ left ventricular wall can be better dis-
tinguished from the liver due to a more rapid liver clearance of 
18F-flurpiridaz compared to 13N-ammonia. Modified from Higu-
chi et al. [32] © by the Society of Nuclear Medicine and Molecular 
Imaging, Inc.
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imaging agent, the inferior/left ventricular wall can be bet-
ter distinguished from the liver [32]. Figure 3 displays a 
head-to-head comparison of 18F-flurpiridaz and 18F-FBnTP 
in a rat model of short-term occlusion and reperfusion. For 
the latter radiotracer, retention stability over time was con-
firmed, while 18F-flurpiridaz showed slow restoration over 
time. Differences may be explained by the underlying uptake 
mechanisms: 18F-flurpiridaz targets mitochondrial complex 
I, while 18F-FBnTP localizes to mitochondria due to mem-
brane potential [33]. The observed kinetics (redistribution 
after reperfusion) may allow for the use of 18F-flurpiridaz 
in a similar way to clinical protocols for the diagnosis of 
CAD with conventional stress/rest 201TI perfusion protocols 
or for the assessment of myocardial viability [32, 34]. In a 
permanent and transient occlusion model of the left coronary 
artery, uptake defect assessed by 18F-flurpiridaz closely cor-
related with histological measured scar sizes confirmed by 
2,3,5-triphenyltetrazolium chloride staining [35]. In a pig 
model, Guehl et al. demonstrated that accurate rest and stress 
blood flow estimations with 18F-flurpiridaz are feasible, even 
in less than 15 min of PET acquisition time by using a single-
scan rest-stress method, which further emphasizes the practi-
cality of this radiotracer in clinical routine [36]. Also in a pig 
model, Sherif et al. showed that 18F-flurpiridaz retention and 
standardized uptake values (SUVs) correlated with absolute 
MBF values at rest and pharmacological stress. As such, 
SUVs may be used as a substitute for absolute blood flow. 
As SUV does not require determination of radiotracer input 
function, tracer injection and exercise treadmill or bicycle 
stress test protocols could be performed outside the scanner. 
From a practical standpoint, such an approach may facilitate 
flow estimation in clinical routine [37]. By comparison with 
radioactive microsphere-derived blood flow in a pig model, a 
high agreement rate with regional MBF using 18F-flurpiridaz 
was achieved, even over a wide flow range [38].
Clinical studies
In a phase I trial enrolling healthy volunteers, a sustained 
retention was recorded up to 5 h post-injection and the radi-
otracer was well tolerated in all 13 subjects [39]. Clear and 
homogenous delineation of the myocadium was appreci-
ated up to 5 h after administration, while liver clearance 
was observed 2 h post-injection [39]. Thus, the radiophar-
maceutical is present in the myocardium to allow for an 
administration of the radiotracer at peak treadmill exercise. 
Moreover, kinetic studies demonstrated that imaging can 
be performed immediately after completing the exercise 
protocol and thus, 18F-flurpiridaz may identify even sub-
tle stress-induced wall motion abnormalities (compared to 
SPECT with 99mTc agents, which generally involve imag-
ing at least 30 min post-injection) [25]. Apart from that, 
Packard et al. enrolled seven healthy subjects with a low 
likelihood of myocardial ischemia and 8 CAD patients using 
18F-flurpiridaz. Notably, such a study design provided a wide 
range of MBF. In patients with no stress-inducible ischemia, 
no significant differences in MBF (either at rest or adenosine 
stress) and myocardial flow reserve (MFR) were recorded. 
This was in contradistinction to CAD subjects: lower MBF 
in diseased vascular segements after adenosine stress was 
noted and therefore, also a reduction in MFR [40]. Berman 
et al. evaluated the efficacy and safety profile of 18F-flurpiri-
daz in a phase II trial. In 143 subjects from 21 different 
study sites, stress-rest PET and 99mTc sestamibi SPECT 
were performed, while the latter imaging modality served 
as a comparator. The certainty of interpretation, which was 
recorded by three blinded readers in a binary fashion (abnor-
mal vs. normal), was considerably higher for PET (90.8% vs. 
SPECT, 70.9%). In 86 patients, who also underwent invasive 
coronary angiography (ICA, as a reference standard for coro-
nary stenosis), PET revealed a higher sensitivity compared 
to SPECT, while specificity remained similar. Of note, in 
patients suffering from CAD (detected on invasive proce-
dures), the magnitude of the reversible defect assessed with 
PET was larger than with SPECT. Figure 4 displays a mis-
match of 18F-flurpiridaz PET MPI versus 99mTc-sestamibi 
SPECT MPI in an 82-year old male with an occluded native 
proximal left anterior descending (LAD) coronary artery 
and an occluded left internal mammary graft to the LAD. 
On 18F-flurpiridaz PET MPI, a reversible perfusion defect 
throughout the territory of the occluded proximal LAD was 
noted; the 99mTc-sestamibi images showed only a moderate 
perfusion defect in the distal LAD territory [41]. Assessing 
the summed difference score for 18F-flurpiridaz MPI and 
99mTc-sestamibi MPI, stress induced perfusion abnormali-
ties in patients with multivessel CAD were significantly 
higher with PET MPI [42]. Recently, Bateman et al. reported 
on 795 subjects from 72 international sites and described 
previous results of the first Phase III trial. The authors 
Fig. 3  Head-to-head comparison of both 18F-labeled myocardial per-
fusion (MPI) PET radiotracers in a rat model of short-term occlusion 
and reperfusion. Radiotracers  [18F-flurpiridaz and 18F-fluorobenzyl-
triphenyl-phosphonium (18F-FBnTP)] were injected during ischemia. 
18F-flurpiridaz showed slow restoration of uptake, while 18F-FBnTP 
remained stable over time, i.e. stability and lack of washout was con-
firmed for 18F-FBnTP [17]. Differences may be explained by different 
uptake mechanisms of both radiotracers [33]. Modified from Higuchi 
et al. [32, 33] © by the Society of Nuclear Medicine and Molecular 
Imaging, Inc
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noted superior diagnostic performance characteristics for 
18F-flurpiridaz relative to SPECT MPI for the assessment 
of CAD in obese patients [43]. The recently launched, pro-
spective, international, multi-center, open-label AURORA 
study (second Phase III study, ClinicalTrials.gov Identifier: 
NCT03354273) will include subjects with suspected CAD 
scheduled for ICA and both SPECT and PET MPI will be 
carried out prior to intervention. The primary endpoint is 
diagnostic efficacy of 18F-flurpiridaz PET MPI in detecting 
significant CAD [44, 45].
18F‑labeled radiotracers for MPI: 18F‑FBnTP
The lipophilic cation 18F-FBnTP also accumulates in myo-
cardial mitochondria [46]. In mongrel dogs, uptake and 
retention kinetics were tested in vivo and 18F-FBnTP reached 
its plateau in the left ventricle 5 min after radiotracer admin-
istration. A delineation of the myocardium was still seen 
90 min post-injection. In addition to that, the metabolite 
concentration in the blood was considerably low and the 
heart-to-liver ratio was 1.2 after 60 min. The heart-to-lung 
ratio was 12:1 (5 min post-injection), which was much 
higher than reported for 99mTc-labeled SPECT agents (2:1) 
in the same species. Thus, one may speculate that the lower 
background activity leads to better imaging contrast relative 
to SPECT counterparts [47, 48]. In addition, 18F-FBnTP was 
also compared to 99mTc-tetrofosmin SPECT in vivo by using 
various degrees of coronary artery stenosis: 17 dogs with 
different degrees of stenosis of LAD or circumflex coronary 
arteries were enrolled. Microsphere flow was assessed with 
radioactive micropsheres, which allow for distinction of true 
myocardial blood flow in ischemic versus non-ischemic beds 
of the left ventricle. Compared to 99mTc-tetrofosmin, supe-
rior diagnostic performance for 18F-FBnTP was reported, 
in particular for the assessment of mild or severe stenosis 
[49]. To reveal further insights into kinetics of 18F-FBnTP, 
short transient coronary artery occlusion (ligation of the left 
coronary artery, 2 min) was induced in Wistar rats, which 
was followed by reperfusion. PET imaging with 18F-FBnTP 
showed that the radiotracer remained stable demonstrating 
no washout or redistribution and matched histologically 
proven defect areas [33]. Recently, in a rat model of autoim-
mune myocarditis, the longitudinal imaging characteristics 
of 18F-FDG were investigated and 18F-FBnTP was used as 
a reference perfusion marker [50]. Albeit this radiotracer 
is used in a preclinical setting over the last years, human 
data are still lacking and thus, if a more widespread adop-
tion is envisaged, further clinical trials are warranted. In 
addition to 18F-FBnTP, 18F-labeled fluoroalkylphospho-
nium derivatives (18F-FATPs) have been synthesized as 
well: these are (5-18F-fluoropentyl)triphenylphosphonium 
cation (18F-FPTP), (6-18F-fluorohexyl)triphenylphospho-
nium cation (18F-FHTP), and (2-(2-18F-fluoroethoxy)
ethyl)triphenylphosphonium cation (18F-FETP). Compared 
with 13N-ammonia in a rat model of coronary occlusion, 
18F-FATPs showed excellent image quality, along with rapid 
liver and lung clearance [51].
Table 1 summarizes key properties of 18F-labeled radi-
otracers for PET MPI. Supplementary Table 1 displays char-
acteristics of established PET MPI agents and the novel PET 
agent 18F-flurpiridaz.
Future directions
18F-labeled radiotracers allow for an improved target-
to-background ratio compared to commonly used PET 
MPI agents, which in turn leads to higher imaging qual-
ity [32]. Thus, given the superior imaging characteristics 
of 18F-labeled PET MPI radiotracers compared to other 
SPECT or PET MPI competitors, it is possible that these 
novel radiotracers further contribute to an even more 
Fig. 4  FLUR PET and MIBI SPECT images from an 82-year-old 
man. The FLUR PET (top) and MIBI SPECT (bottom) images from 
an 82-year-old man with shortness of breath and an occluded native 
proximal left anterior descending (LAD) coronary artery and an 
occluded left internal mammary graft to the LAD and no other sig-
nificant native CAD. The FLUR images show a severe reversible per-
fusion defect throughout the territory of the occluded proximal LAD, 
whereas the MIBI images show only a moderate perfusion defect in 
the distal LAD territory (apical slices). FLUR = Flurpiridaz F 18; 
MIBI = Tc-99m sestamibi. Reprinted from the Journal of the Ameri-
can College of Cardiology (JACC), 61(4), Daniel S. Berman, Jamshid 
Maddahi, B. K. Tamarappoo, Johannes Czernin, Raymond Taillefer, 
James E. Udelson, C. Michael Gibson, Marybeth Devine, Joel Laze-
watsky, Gajanan Bhat, Dana Washburn, Phase II safety and clinical 
comparison with single-photon emission computed tomography myo-
cardial perfusion imaging for detection of coronary artery disease: 
flurpiridaz F 18 positron emission tomography, 469-77, Copyright 
(2013), with permission from Elsevier [41]
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tailored treatment approach for ischemic heart patients. 
Notably, the extraction fraction of those radiotracers at 
various flow rates open the door for optimal absolute MBF 
quantification [40]. Cutoff values of both MBF and MFR 
could be established with those radiotracers and thus, 
could be used for risk stratification [40]. This would apply 
to different subgroups in a clinical context which are at 
higher risk of cardiac events, such as diabetes or chronic 
kidney diseases [52]. The latter group is of great inter-
est, as cardiovascular disease is the main cause of death 
among patients suffering from severe renal dysfunction 
[53]. However, conventional SPECT MPI cannot identify 
high-risk patients across a wide spectrum of renal (mal)
function and thus, novel approaches using 18F PET MPI 
radiotracers may have an increased prognostic capability 
[54]. In addition, quantification of MBF (assessed by 82Rb 
PET) in patients prior to heart transplantation can also 
identify subjects at high risk of suffering from later clini-
cal events [55]. However, the longer half-life of 18F PET 
MPI along with their superior imaging quality may allow 
for a more practical adoption in clinical routine and a more 
thorough evaluation of the perfusion status in heart trans-
plant recipients. Other applications of such radiotracers 
include chest pain with normal findings on coronary angi-
ography [52]. In a similar vein like for MPI PET agents, a 
recent shift from established cardiac neuronal PET agents 
(11C-hydroxyephedrine) towards novel 18F-labeled PET 
tracers to measure cardiac nerve integrity has been noted, 
e.g. by the use of the myocardial nerve imaging agent 18F-
LMI1195 [56]. Thus, in a dual-tracer approach, both newly 
introduced 18F radiotracers (18F-flurpiridaz for MBF and 
18F-LMI1195 for cardiac nerve integrity) could be used. 
Such a global functional assessment of the heart has been 
also previously tested in a rat model of ischemia (with 
11C-HED and 201TI for perfusion): compared to the perfu-
sion defect areas, a larger 11C-HED uptake defect in both 
subacute and chronic phases was noted [57]. Thus, further 
clinical applications, preferably with 18F-labeled cardiac 
perfusion/nerve tracers, which offer superior imaging 
quality, would be of great interest.
Table 1  Advantages and 
limitations of the reviewed 
18F-labeled PET radiotracers 
for MPI, namely 18F-flurpiridaz 
and 18F-fluorobenzyltriphenyl-
phosphonium (18F-FBnTP)
SPECT single photon emission tomography, CAD coronary artery disease, FDA Food and Drug Adminis-
tration
18F MPI PET radiotracers Advantages Limitations
18F-flurpiridaz • Considerable high first-pass extraction of > 90% 
[27, 28]
• Almost linear correlation between tracer uptake 
and cardiac blood flow in isolated perfused rat 
hearts [28]
• Radiotracer redistribution after reperfusion, 
i.e. 18F-flurpiridaz may be suitable for clinical 
protocols similar to conventional stress/rest 201TI 
perfusion protocols or assessment of myocardial 
viability [32]
• Phase I: radiotracer present up to 5 h post-
injection, i.e. injection at peak treadmill exercise 
is feasible [39]
• Phase II: compared to stress-rest SPECT MPI, 
PET MPI with superior performance characteris-
tics for overall CAD diagnosis [41]
• First Phase III study: superior perfusion defect 
detection of 18F-flurpiridaz relative to SPECT 
MPI for the assessment of CAD in obese sub-
jects [43]
• Second Phase III study (AURORA): will assess 
the efficacy of 18F-flurpiridaz PET MPI in 
detecting significant CAD compared to SPECT 
MPI in patients scheduled for invasive coronary 
angiography [44, 45]
• Limited to academic 
centers
• Cyclotron production
• No FDA approval yet
• Cost-effectiveness 
data are lacking
18F-FBnTP • Superior diagnostic performance for 18F-FBnTP 
compared to SPECT MPI in dogs [49]
• Lack of redistribution in a rat model of short 
transient coronary artery occlusion (2 min) and 
reperfusion (i.e. tracer injection remote from the 
imaging device may be feasible, e.g. in a chest 
pain unit) [33]
• No larger clinical 
trials
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Conclusions
18F-labeled radionuclides for PET MPI perform well in 
assessing the defect size in CAD patients. First, they are 
less expensive to produce and may also be distributed using 
delivery systems from central cyclotron facilities [23]. Sec-
ond, the longer half-life of 18F-labeled MPI agents also allow 
for delayed imaging protocols, which in turn may allow for 
physical exercise stress testing protocols outside of the 
scanner [17]. In light of its excellent extraction fraction, 
18F-flurpiridaz has very favorable characteristics as a PET 
MPI agent and phase II/III trials have reported on a supe-
rior diagnostic performance relative to common SPECT MPI 
agents [39, 41, 43]. In the currently recruiting AURORA 
trial, subjects referred for ICA because of suspected CAD 
will undergo both SPECT and PET MPI prior to interven-
tion [44, 45]. The results may reveal further insights into 
the efficacy of 18F-flurpiridaz PET MPI in detecting signifi-
cant CAD. However, MPI (either with PET or SPECT) still 
remains underrepresented in some countries: for instance, 
in Germany, CAD diagnosis seems to be mainly shifted 
directly to invasive angiographic procedures, which in turn 
leads to less requests of such tests in clinical routine [58].
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